Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Isabell Xiang Ge"'
Autor:
Anna Lena Illert, Nikolas von Bubnoff, Rouven Hoefflin, Michel Eisenblaetter, Philipp Poxleitner, Patrick Metzger, Nico Buettner, Florian Scherer, Anna-Lena Geißler, Alexander Keller, Melanie Boerries, Alexandra Kutilina, Ralph Fritsch, Christine Dierks, Jesus Duque-Afonso, Adriana Lazarou, Isabell Xiang Ge, Justus Duyster, Steffen Heeg, Frank Meiss, Andreas Tzschach, Anna Verena Frey, Cornelius Miething, Gian Kayser, Simone Hettmer, Martin Werner, Leman Mehmed, Heiko Becker, Justyna Rawluk, Julius Wehrle, Dieter Henrik Heiland, Khalid Shoumariyeh, Markus Grabbert, Tilman Brummer, Juri Ruf, Thalia Erbes, Christoph Peters, Konrad Aumann, Kai Berner, Maria Elena Hess, Meike Reiser, Martin Boeker, Anita Kleiber, Silke Lassmann, Henning Schäfer
Publikováno v:
Cancers
Volume 13
Issue 5
Cancers, Vol 13, Iss 1151, p 1151 (2021)
Volume 13
Issue 5
Cancers, Vol 13, Iss 1151, p 1151 (2021)
Simple Summary Access to molecular cancer treatments outside of clinical trials is limited and the benefit of molecular-guided, individualized patient care in patients with cancer progression after standard treatment is unclear. We here present the f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10ed1754b0aaa53292ea022f515d88c1
Autor:
Isabell Xiang Ge, Julius Wehrle, Simone Hettmer, Martin Werner, Meike Reiser, Volker Brass, Melanie Boerries, Silke Lassmann, Christoph Peters, Steffen Heeg, Agnes Csanadi, Frank Meiss, Lisa Fauth, Henning Schäfer, Rainer Claus, Justus Duyster, Anna-Lena Geißler, Rouven Hoefflin, Dieter Henrik Heiland, Nikolas von Bubnoff, Dagmar von Bubnoff, Friedrich Stock, Patrick Metzger, Thalia Erbes, Elke Maria Botzenhart, Christine Dierks, Justyna Rawluk, Britta Weddeling, Gian Kayser, Ralph Fritsch, Martin Boeker, Leman Mehmed, Hauke Busch, Cornelius Miething, Tilman Brummer
Publikováno v:
JCO Precision Oncology
Purpose Dramatic advances in our understanding of the molecular pathophysiology of cancer, along with a rapidly expanding portfolio of molecular targeted drugs, have led to a paradigm shift toward personalized, biomarker-driven cancer treatment. Here
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::442a7571988f939d44cb8161919bf060
https://doi.org/10.1200/po.18.00105
https://doi.org/10.1200/po.18.00105